LAVA Therapeutics Postpones Extraordinary General Meeting
LAVA Therapeutics N.V. has decided to move its planned Extraordinary General Meeting of Shareholders to early November 2025. This decision comes after the company recognized the need for additional time to address potential liabilities and ensure the net cash provided to shareholders is clear and definitive.
Strategic Focus on Acquisition
This adjustment aims to facilitate further discussions regarding the company's previously announced acquisition by XOMA Royalty Corporation. LAVA Therapeutics aims to finalize this transaction in the fourth quarter of 2025. It is crucial for the company to solidify the details surrounding the offer to purchase all outstanding common shares.
CEO's Commitment to the Deal
Owen Hughes, CEO of XOMA Royalty, expressed a strong commitment to the transaction, stating, "We are committed to closing this transaction and look forward to working collaboratively to finalize LAVA’s cash forecast, facilitating a swift resolution of our agreement." This shared ambition reflects the dedication to ensuring the deal benefits all stakeholders involved.
EGM Rescheduling Insights
The reconvened EGM will take place in early November, though the exact date and location have yet to be announced by the company. Importantly, votes cast by shareholders for the initially planned meeting will not count toward the revised meeting's agenda. Shareholders as of the new record date will need to cast their votes again.
About LAVA Therapeutics
LAVA Therapeutics is at the forefront of biopharmaceutical innovation, specializing in the development of bispecific gamma delta T cell engagers through its proprietary Gammabody platform. This technology includes promising treatments such as JNJ-89853413 for hematologic cancers and PF-08046052 targeting solid tumors, both developed in partnership with major pharmaceutical companies like Johnson & Johnson and Pfizer.
Innovative Cancer Therapies
LAVA Therapeutics is focused on enhancing the therapeutic landscape for patients with cancers. Their Gammabody platform has the potential to revolutionize treatment by promoting targeted immune responses against cancer cells, showcasing the company's commitment to addressing critical medical needs.
Contacting LAVA Therapeutics
For further information about LAVA Therapeutics, stakeholders can reach out to Fred Powell at +1 800-311-6892 or via email at ir@lavatherapeutics.com.
Frequently Asked Questions
What is the reason for postponing the EGM?
LAVA Therapeutics postponed the EGM to ensure clarity on potential liabilities and to ensure shareholder interests are fully considered in the ongoing acquisition discussions.
When will the reconvened EGM occur?
The reconvened EGM is expected to be held in early November 2025, with the specific date to be announced later.
What is the focus of LAVA Therapeutics?
LAVA Therapeutics focuses on developing innovative biopharmaceutical treatments, particularly bispecific gamma delta T cell engagers for cancer therapies.
How can shareholders participate in the reconvened EGM?
Shareholders on the record date will need to cast their votes again at the reconvened EGM, as votes from the previously scheduled meeting will not carry over.
Who can I contact for more information about LAVA Therapeutics?
Shareholders and interested parties can contact LAVA Therapeutics through Fred Powell at +1 800-311-6892 or email at ir@lavatherapeutics.com.
